Uses
NLRP3-IN-9 is a potent NLRP3 inhibitor. NLRP3-IN-9 inhibits IL-1β release. NLRP3-IN-9 reduces inflammation and mechanical hyperalgesia. NLRP3-IN-9 has the potential for the research of gout[1].
in vivo
NLRP3-IN-9 (3, 10 mg/kg; i.p.) reduces inflammation and mechanical hyperalgesia in a mouse model of acute gout[1].
| Animal Model: | 3-4 month old male and female C57BL/6J WT and NLRP3-KO mice[1] |
| Dosage: | 3, 10 mg/kg |
| Administration: | I.p. |
| Result: | Reduced paw swelling by 40% in males and 33% in females at 3 mg/kg, and 66% in males and 52% in females at 10 mg/kg in WT mouse. |
References
[1] Narros-Fernández P, et al. Synthesis and Pharmacological Evaluation of New N-Sulfonylureas as NLRP3 Inflammasome Inhibitors: Identification of a Hit Compound to Treat Gout. J Med Chem. 2022 Apr 28;65(8):6250-6260. DOI:
10.1021/acs.jmedchem.2c00149
![2-Furansulfonamide, N-[[(3,5-dimethylphenyl)amino]carbonyl]-4-(1-hydroxy-1-methylethyl)-, sodium salt, ion(1-) (1:1) Structure](https://www.chemicalbook.com/CAS/20211123/GIF/2768759-64-2.gif)